Molecular Remodeling in Human Heart Failure⁎⁎Editorials published in the Journal of the American College of Cardiology reflect the views of the authors and do not necessarily represent the views of JACC or the American College of Cardiology.  by Cappola, Thomas P.
M
i
T
P
T
p
t
a
S
s
c
m
t
m
a
c
d
s
m
s
s
c
t
a
r
c
f
m
p
(
s
o
fi
d
t
p
c
s
g
h
m
w
u
d
d
m
e
p
i
c
w
b
c
l
a
o
4
i
f
e
e
B
n
H
r
r
m
a
o
s
e
s
m
p
f
w
a
s
n
c
a
w
n
c
s
*
v
A
P
D
D
R
Journal of the American College of Cardiology Vol. 51, No. 2, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc. doi:10.1016/j.jacc.2007.09.028EDITORIAL COMMENT
olecular Remodeling
n Human Heart Failure*
homas P. Cappola, MD, SCM
hiladelphia, Pennsylvania
he past decade has seen an explosion of research into the
athogenesis of cardiac hypertrophy and remodeling (1). At
he cellular level, remodeling can be regarded, in large part,
s the response of cardiac myocytes to biomechanical stress.
tressors such as pressure or volume load, reactive oxygen
pecies, cytokines, and circulating neurohormones activate a
omplex network of signaling pathways within cardiac
yocytes. These pathways converge on a core set of cardiac
ranscription factors, co-regulators, and as shown recently,
icro ribonucleic acids (2,3) to alter cardiac gene expression
nd induce myocyte hypertrophy and dysfunction. These
hanges are similar to those observed during fetal cardiac
evelopment, and the process of hypertrophy is often de-
cribed as reactivation of a “fetal gene program.” Although
any changes occur, the most well-characterized include a
hift in expression of contractile isoforms, increased expres-
ion of natriuretic peptides, and alterations in expression of
alcium cycling genes. Hence, animal models have shown
hat gross chamber remodeling is accompanied by a char-
cteristic “molecular remodeling” believed to play a causative
ole in the pathogenesis of heart failure.
See page 129
Translating these findings to human subjects has been
hallenging. To study molecular aspects of human heart
ailure, investigators have capitalized on situations in which
yocardium can be conveniently obtained with minimal
atient risk, such as at the time of cardiac transplantation
4,5) or placement of ventricular assist devices (6–9). These
tudies have determined that molecular remodeling does
ccur in human heart failure in a manner that parallels
ndings in animal models. Work from our own group has
emonstrated that many of the same hypertrophic transcrip-
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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iagnostics, and the National Institutes of Health (K23HL071562 and
01HL088577).ion factors identified in murine models might mediate this
rocess (5). Importantly, heart failure therapies that lead to
linical improvement reverse the molecular changes ob-
erved in heart failure, so that expression of the fetal cardiac
ene program fades as ventricular function improves. This
as been demonstrated in human subjects with serial assess-
ents of cardiac gene expression before and after treatment
ith beta-blockers (10) and before and after mechanical
nloading with ventricular assist devices (6–9).
In this issue of the Journal, Vanderheyden et al. (11)
emonstrate that, like beta-blockers and ventricular assist
evices, cardiac resynchronization therapy also causes “reverse
olecular remodeling.” The authors performed left ventricular
ndomyocardial biopsies in a small cohort of stable heart failure
atients undergoing elective implantation of biventricular pac-
ng devices and repeated these biopsies after 4 months of
ardiac resynchronization. Compared with control subjects
ith normal ventricular function, heart failure patients at
aseline showed decreased expression of alpha-myosin heavy
hain (-MHC), -MHC, sarcoplasmic-endoplasmic reticu-
um calcium ATPase 2-a (SERCA2a), and phospholamban
nd increased expression of brain natriuretic peptide (BNP), all
f which are typical features of heart failure in humans. After
months of resynchronization therapy, patients who showed
mprovement in ventricular function and reduction in heart
ailure symptoms also showed restoration of cardiac gene
xpression toward a more normal pattern, with an increase in
xpression of -MHC and SERCA2a and a decrease in BNP.
y contrast, patients who showed no clinical response showed
o change in molecular profile after resynchronization therapy.
ence, clinical response was associated with reverse molecular
emodeling and a “tuning down” of the fetal gene program.
The major strengths of this study are the focus on highly
elevant molecular markers of heart failure, the use of repeated
easures in the same patients to reduce variability, and the
ssessment of gene expression in the left ventricle, the chamber
f interest, as opposed to biopsies of the right ventricular
eptum. It was not feasible, like many studies involving
ndomyocardial biopsy, to study a large population, and the
mall sample size and small amount of available tissue are the
ajor study limitations. As a result, the authors were under-
owered to determine whether gene expression changes dif-
ered depending on the underlying etiology of heart failure,
hich has been suggested by previous studies (4). In addition,
ssessing a larger number of genes with more comprehensive
trategies, such as whole-genome expression profiling, was also
ot feasible. That said, the overall study findings are highly
ompelling when viewed in the larger context of published data
nd they have since been verified by an independent group
ith similar approaches (12).
Thus, highly effective heart failure therapies, including
eurohormonal blockade, mechanical unloading, and now
ardiac resynchronization, improve cardiac function in as-
ociation with reverse molecular remodeling. These consis-
ent findings have several clinical implications. First, they
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Editorial Comment January 15, 2008:137–8uggest that molecular markers that track the fetal gene
rogram could serve as clinically useful biomarkers of heart
ailure progression. Circulating BNP has already become a
tandard in this area, but it seems likely that expanded
anels of biomarkers could be even more informative.
eveloping these “molecular signatures” will require studies
n large clinical cohorts that demonstrate their ability to
redict future clinical events and to predict response to
pecific heart failure therapies. In addition, obtaining the
olecular signature must be convenient enough to repeat
ver time, which is currently not the case for gene expres-
ion signatures obtained via endomyocardial biopsy.
Second, because cardiac gene expression seems to be a
nal common mediator of heart failure, it should be tested
s a direct therapeutic target. Several strategies are evolving
o accomplish this, including the use of histone deacetylase
nhibitors (13) and short hairpin ribonucleic acid (14) to alter
xpression of endogenous myocardial genes and the use of
denoviral vectors to introduce exogenous genes to improve
ardiac function. For example, the ongoing CUPID (Safety
tudy of Gene Transfer Agent MYDICAR [AAV1/
ERCA2a] to Treat Heart Failure) clinical trial (15) is
urrently testing the safety and early efficacy of an intracoronary
ERCA2a transgene as a strategy to improve cardiac function
n chronic heart failure (16). This trial will provide some of the
rst human data testing molecular therapy for heart failure.
Finally, the logistical challenges of studying human car-
iac gene expression emphasize the need for newer nonin-
asive approaches to study molecular aspects of cardiac
emodeling in human subjects. Many strategies are evolving
o do this, including novel circulating biomarkers, studies of
nherited gene variation in hypertrophic signaling pathways,
nd molecular imaging. These techniques will undoubtedly
elp us test the clinical relevance of mechanisms of cardiac
emodeling discovered in animal models and thereby iden-
ify novel therapeutic targets for human heart failure.
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